Search Results

There are 17492 results for: content related to: Green Process Chemistry in the Pharmaceutical Industry: Recent Case Studies

  1. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 7, July 2011, Pages: 604–614, C. G. Patel, D. Kornhauser, N. Vachharajani, B. Komoroski, E. Brenner, M. Handschuh del Corral, L. Li and D. W. Boulton

    Version of Record online : 24 MAY 2011, DOI: 10.1111/j.1463-1326.2011.01381.x

  2. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 6, June 2011, Pages: 567–576, A. Pfützner, E. Paz-Pacheco, E. Allen, R. Frederich, R. Chen and for the CV181039 Investigators

    Version of Record online : 20 APR 2011, DOI: 10.1111/j.1463-1326.2011.01385.x

  3. You have free access to this content
    Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 6, June 2009, Pages: 611–622, M. Jadzinsky, A. Pfützner, E. Paz-Pacheco, Z. Xu, E. Allen, R. Chen and CV181-039 Investigators

    Version of Record online : 6 MAY 2009, DOI: 10.1111/j.1463-1326.2009.01056.x

    Corrected by:

    Erratum

    Vol. 12, Issue 5, 462, Version of Record online: 30 MAR 2010

  4. You have free access to this content
    Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 72, Issue 1, July 2011, Pages: 92–102, Vijay V. Upreti, David W. Boulton, Li Li, Agatha Ching, Hong Su, Frank P. LaCreta and Chirag G. Patel

    Version of Record online : 9 JUN 2011, DOI: 10.1111/j.1365-2125.2011.03937.x

  5. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 6, June 2011, Pages: 523–532, M. Nowicki, I. Rychlik, H. Haller, M. L. Warren, L. Suchower, I. Gause-Nilsson and for the D1680C00007 Investigators

    Version of Record online : 20 APR 2011, DOI: 10.1111/j.1463-1326.2011.01382.x

  6. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 7, July 2015, Pages: 630–638, G. Schernthaner, S. Durán-Garcia, M. Hanefeld, G. Langslet, L. Niskanen, C. J. Östgren, E. Malvolti and E. Hardy

    Version of Record online : 7 APR 2015, DOI: 10.1111/dom.12461

  7. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 5, May 2008, Pages: 376–386, J. Rosenstock, S. Sankoh and J. F. List

    Version of Record online : 18 MAR 2008, DOI: 10.1111/j.1463-1326.2008.00876.x

  8. Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 50, Issue 10, October 2010, Pages: 1211–1216, Chirag G. Patel, Jenny Zhang, Li Li, Lara Gooding, Robert Croop, Tong Li and David W. Boulton

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009360532

  9. You have full text access to this OnlineOpen article
    Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects

    Pharmacology Research & Perspectives

    Volume 3, Issue 6, December 2015, Blisse Vakkalagadda, Marion L. Vetter, Jignasa Rana, Charles H. Smith, Jian Huang, Jennifer Karkas, David W. Boulton and Frank LaCreta

    Version of Record online : 12 JAN 2016, DOI: 10.1002/prp2.201

  10. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 5, May 2015, Pages: 487–494, G. Leibowitz, A. Cahn, D. L. Bhatt, B. Hirshberg, O. Mosenzon, C. Wei, G. Jermendy, W. H.-H. Sheu, J. L. Sendon, K. Im, E. Braunwald, B. M. Scirica and I. Raz

    Version of Record online : 25 FEB 2015, DOI: 10.1111/dom.12445

  11. You have free access to this content
    Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

    International Journal of Clinical Practice

    Volume 67, Issue 4, April 2013, Pages: 307–316, Burkhard Göke, Baptist Gallwitz, Johan G. Eriksson, Åsa Hellqvist and Ingrid Gause-Nilsson

    Version of Record online : 25 JAN 2013, DOI: 10.1111/ijcp.12119

  12. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 4, April 2012, Pages: 365–371, V. Fonseca, T. Zhu, C. Karyekar and B. Hirshberg

    Version of Record online : 18 JAN 2012, DOI: 10.1111/j.1463-1326.2011.01553.x

  13. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 6, June 2012, Pages: 481–492, K. R. Gerrald, E. Van Scoyoc, R. C. Wines, T. Runge and D. E. Jonas

    Version of Record online : 27 DEC 2011, DOI: 10.1111/j.1463-1326.2011.01540.x

  14. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 9, September 2011, Pages: 850–858, R. R. Henry, S. R. Smith, S. L. Schwartz, S. R. Mudaliar, C. F. Deacon, J. J. Holst, R. Y. Duan, R. S. Chen and J. F. List

    Version of Record online : 26 JUL 2011, DOI: 10.1111/j.1463-1326.2011.01417.x

  15. A Pharmacometric Approach to Quantify the Impact of Chronic Kidney Disease and Hemodialysis on Systemic Drug Exposure: Application to Saxagliptin

    The Journal of Clinical Pharmacology

    Volume 52, Issue S1, January 2012, Pages: 126S–133S, Dr. Liping Zhang, Dr. David W. Boulton and Dr. Marc Pfister

    Version of Record online : 23 APR 2013, DOI: 10.1177/0091270011415627

  16. Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 5, May 2010, Pages: 463–484, Dr. Joshua J. Neumiller, Dr. Lindy Wood and Mr. R. Keith Campbell

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.5.463

  17. Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen®, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 12, December 2012, Pages: 1155–1157, V. V. Upreti, C. B. Hsiang, L. Li, X. Xu, F. P. LaCreta and D. W. Boulton

    Version of Record online : 9 JUL 2012, DOI: 10.1111/j.1463-1326.2012.01635.x

  18. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

    International Journal of Clinical Practice

    Volume 64, Issue 12, November 2010, Pages: 1619–1631, B. Göke, B. Gallwitz, J. Eriksson, Å. Hellqvist, I. Gause-Nilsson and for the D1680C00001 Investigators

    Version of Record online : 16 SEP 2010, DOI: 10.1111/j.1742-1241.2010.02510.x

  19. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

    Diabetes/Metabolism Research and Reviews

    Volume 30, Issue 7, October 2014, Pages: 556–569, Boaz Hirshberg, Artist Parker, Helen Edelberg, Mark Donovan and Nayyar Iqbal

    Version of Record online : 15 OCT 2014, DOI: 10.1002/dmrr.2502

  20. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

    Diabetes/Metabolism Research and Reviews

    Volume 26, Issue 7, October 2010, Pages: 540–549, André J. Scheen, Guillaume Charpentier, Carl Johan Östgren, Åsa Hellqvist and Ingrid Gause-Nilsson

    Version of Record online : 7 SEP 2010, DOI: 10.1002/dmrr.1114